A retrospective review of heart transplant recipients has indicated the possible involvement of Lp(a) in the development of cardiac allograft vasculopathy (CAV) – a major cause of morbidity and mortality after heart transplantation.
AstraZeneca has provided a sponsorship grant towards this independent programme.